Finished product reference
Ritonavir
Capsule · Oral · 100 mg
- List code
- 12455
- Pharmacologic class
- Cytochrome P450 3A Inhibitor · Protease Inhibitor
WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism of certain drugs.
What it is and how it works
Mechanism of Action Ritonavir is an antiretroviral drug .
Mechanism class: HIV Protease Inhibitors · Cytochrome P450 3A Inhibitors · Cytochrome P450 2D6 Inhibitors
Indications
tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. NORVIR oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection. NORVIR tablets are HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection NORVIR oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection
Dosage and administration (summary)
Adult patients: 600 mg twice-day with meals Pediatrics patients: Do not exceed 600 mg twice daily dose with meals for children greater than one month of age. The dose is based on body surface area Use NORVIR oral powder only for dosing increments of 100 mg Follow the Instructions for Use for preparation and administration of NORVIR oral powder Dose modification for NORVIR is necessary when used with other protease inhibitors General Administration Recommendations NORVIR must be used in combination with other antiretroviral agents. Administer NORVIR orally. Swallow NORVIR tablets whole. Do not chew, break or crush NORVIR tablets. Take NORVIR with meals.
Contraindications
• Consult the prescribing information of the co-administered protease inhibitor for contraindication information for that product. • NORVIR is contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome) to ritonavir or any of its ingredients.
Warnings and precautions
The following have been observed in patients receiving NORVIR: The concomitant use of NORVIR and certain other drugs may result in known or potentially significant drug interactions. Consult the full prescribing information prior to and during treatment for potential drug interactions. ( 5.1 , 7.2 ) Hepatotoxicity: Fatalities have occurred. Monitor liver function before and during therapy, especially in patients with underlying hepatic disease, including hepatitis B and hepatitis C, or marked transaminase elevations ( 5.2 , 8.6 ) Pancreatitis: Fatalities have occurred.
Pregnancy
Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to NORVIR during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.
Storage and supply
The package sizes, strengths, and storage and handling recommendations for NORVIR (ritonavir) tablets and oral powder are shown in the table below. NORVIR Tablets, 100 mg Ritonavir NORVIR Oral Powder, 100 mg Packet Presentation White film-coated ovaloid tablets debossed with “NK” on one side providing 100 mg ritonavir.
Source: Ritonavir (Norvir) — US FDA prescribing information, 2026-07-23, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.